

Summary of status of development and availability of variant¹ influenza A(H3N2) candidate vaccine viruses*

* Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise indicated all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test.

[National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)

29 September 2016

Candidate vaccine viruses

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Minnesota/11/2010	NYMC X-203	Classical	NYMC, USA	CDC, USA NYMC, USA
	NYMC X-203A	Classical	NYMC, USA	CDC, USA NYMC, USA
A/Indiana/10/2011	NYMC X-213	Classical	NYMC, USA	CDC, USA NYMC, USA

Candidate vaccine viruses in preparation

Parent virus	Type of virus or reassortant	Developing Institute	Available from
A/Ohio/28/2016	Classical	NIBSC, UK	Pending
	Reverse genetics	CDC, USA	pending

Institutes contact details for candidate vaccine viruses orders/information:

CDC: dwentworth@cdc.gov (Subject: CVV request)

NIBSC: standards@nibsc.org or enquiries@nibsc.org

NYMC: doris_bucher@nymc.edu

For general enquiries, please contact gisrs-whohq@who.int

For other candidate vaccine viruses and potency testing reagents, please go to <http://www.who.int/influenza/vaccines/virus/en/>

¹ Joint FAO, OIE, WHO announcement of the standardization of terminology for the variant A(H3N2) virus recently infecting humans at http://www.who.int/influenza/gisrs_laboratory/terminology_ah3n2v/